Coronavirus (COVID-19) Vaccine Update
Click here to learn more.
For information about COVID-19 or to view additional resources, please
Study RA101495-02.302 is a multicenter, open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. The visit schedule during the first 12 weeks of Study RA101495-02.302 (RAISE)
UCB RA pharma
Dr. Henry Kaminski